

High Katherine A
Form 4
March 25, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
High Katherine A

(Last) (First) (Middle)

C/O SPARK THERAPEUTICS,
INC., 3737 MARKET STREET,
SUITE 1300

(Street)

PHILADELPHIA, PA 19104

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Spark Therapeutics, Inc. [ONCE]

3. Date of Earliest Transaction
(Month/Day/Year)
03/21/2019

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

See Remarks

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	03/21/2019		M		73,249	A	\$ 3.45	287,717	D
Common Stock	03/21/2019		F		31,653	D	\$ 113.25	256,064	D
Common Stock	03/21/2019		M		5,840	A	\$ 68.45	261,904	D
Common Stock	03/21/2019		M		3	A	\$ 40.44	261,907	D
Common Stock	03/21/2019		M		64,160	A	\$ 68.45	326,067	D

Edgar Filing: High Katherine A - Form 4

Common Stock	03/21/2019	F	49,561	D	\$ 113.255	276,506	D
Common Stock	03/21/2019	M	21,247	A	\$ 40.44	297,753	D
Common Stock	03/21/2019	F	25,993	D	\$ 113.26	271,760	D
Common Stock	03/21/2019	M	15,750	A	\$ 56.17	287,510	D
Common Stock	03/21/2019	F	11,184	D	\$ 113.26	276,326	D
Common Stock	03/21/2019	M	7,875	A	\$ 50.55	284,201	D
Common Stock	03/21/2019	F	5,367	D	\$ 113.26	278,834	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares
Stock Option (right to buy)	\$ 3.45	03/21/2019		M	73,249	<u>(1)</u>	07/02/2024	Common Stock		73,249
Stock Option (right to buy)	\$ 68.45	03/21/2019		M	5,840	<u>(2)</u>	03/15/2025	Common Stock		5,840
Stock Option (right to buy)	\$ 40.44	03/21/2019		M	3	<u>(3)</u>	01/04/2026	Common Stock		3

buy)

Stock Option (right to buy)	\$ 68.45	03/21/2019	M	64,160	<u>(2)</u>	03/15/2025	Common Stock	64,160
Stock Option (right to buy)	\$ 40.44	03/21/2019	M	41,247	<u>(3)</u>	01/04/2026	Common Stock	41,247
Stock Option (right to buy)	\$ 56.17	03/21/2019	M	15,750	<u>(4)</u>	01/17/2027	Common Stock	15,750
Stock Option (right to buy)	\$ 50.55	03/21/2019	M	7,875	<u>(5)</u>	01/17/2028	Common Stock	7,875

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
High Katherine A C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA, PA 19104	X		See Remarks	

Signatures

/s/ Joseph W. La Barge, attorney-in-fact for Katherine A.
High

03/25/2019

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) 25% vested on May 24, 2015, and the remainder vested in equal quarterly installments over the following three years.
- (2) 25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years.
- (3) 25% vested January 5, 2017 and the remainder vests in equal quarterly installments over the following three years.
- (4) 25% vested January 18, 2018 and the remainder vests in equal quarterly installments over the following three years.
- (5) 25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years.

Remarks:

President and Head of Research and Development

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: High Katherine A - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.